HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination
Open Access
- 26 February 2007
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 36-10
- https://doi.org/10.1186/1471-2407-7-36
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Breast-Conserving Therapy after Neoadjuvant Chemotherapy: Long-term ResultsThe Breast Journal, 2006
- Apoptosis induced by neoadjuvant chemotherapy in breast cancerPathology, 2006
- Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristicsNature Clinical Practice Oncology, 2005
- High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancerBreast Cancer Research and Treatment, 2005
- Docetaxel induces cell death through mitotic catastrophe in human breast cancer cellsMolecular Cancer Therapeutics, 2005
- Breast Conservation after Neoadjuvant Chemotherapy for Stage II Carcinoma of the BreastJournal of the American College of Surgeons, 2005
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.Journal of Clinical Oncology, 1997
- Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or MoreJNCI Journal of the National Cancer Institute, 1990
- Anthracyclines.1990